<DOC>
	<DOCNO>NCT01979445</DOCNO>
	<brief_summary>There two separate objective study : 1. demonstrate pharmacodynamic profile patient treat cangrelor switch oral prasugrel administer 30 min cangrelor infusion discontinue 2. demonstrate pharmacodynamic profile patient treat cangrelor switch clopidogrel 600mg administer immediately infusion .</brief_summary>
	<brief_title>Cangrelor Clopidogrel Prasugrel Transition Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . Greater / equal 18 less 75 year age , either sex , race . 2 . Stable coronary artery disease define follow criterion : 1 . Previous myocardial infarction define admission hospital elevation marker injury presence pathologic Qwaves least 2 contiguous electrocardiogram ( ECG ) lead . OR 2 . Previous revascularization PCI CABG , 3 . Treatment ASA 81 mg daily . 1 . Known intolerance contraindication cangrelor prasugrel , ingredient respective formulation . 2 . Any antiplatelet ( aspirin ) anticoagulant medication previous 30 day . 3 . Acute coronary syndrome within previous 12 month . 4 . History bleed diathesis know coagulopathy ; impaired hemostasis : know international normalize ratio ( INR ) &gt; 1.5 ; past present bleed disorder ( include congenital bleeding disorder von Willebrand 's disease hemophilia ) , acquire bleeding disorder , unexplained clinically significant bleeding disorder ; thrombocytopenia ( platelet count le 100,000/ÂµL ) , history thrombocytopenia neutropenia associate clopidogrel . 5 . Anemia ( ie , hematocrit le 35 % ) . 6 . Prior stroke ( type ) , prior cerebral anteriovenous malformation intracranial aneurysm ; recent ( &lt; 1 month ) trauma major surgery ( include bypass surgery ) . 7 . Known suspected pregnancy , lactate female . 8 . Known severe renal insufficiency ( glomerular filtration rate [ GFR ] le 30 mL/min ) . 9 . Inability provide inform consent . 10 . Moderate severe hepatic impairment per investigator discretion ( elevation liver function test [ LFTs ] ) . 11 . Inability swallow oral medication time randomization . 12 . Any clinically significant disease condition affect major organ system , include limited gastrointestinal , renal , hepatic , endocrinologic , bronchopulmonary , neurological , metabolic disease . 13 . Any surgical medical condition , judgment Investigator , might interfere pharmacokinetics , distribution , metabolism , excretion study drug ( applicable ) . 14 . Treatment investigational medicinal product device within 30 day 5 halflives , whichever longer , prior administration drug , plan use investigational medicinal product device . 15 . Subjects , reason , deem Investigator inappropriate study , include subject unable communicate cooperate Investigator . 16 . Subject Investigator his/her deputy , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study . 17 . Active pathological bleeding , history transient ischemic attack .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>CAD</keyword>
</DOC>